Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

December 18, 2017

By Dennis A. Eichenauer, MD

News

Video

In this video reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.

In this video, Dennis A. Eichenauer, MD, of the University of Cologne, Germany, reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Eichenauer gave a presentation on this topic, “Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management,” during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Recent Videos

CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.

The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.

Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.

Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.

Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.

A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.

5 experts in this video

5 experts in this video

Related Content

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

Roman Fabbricatore

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma

Roman Fabbricatore

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

Related Content

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

Roman Fabbricatore

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma

Roman Fabbricatore

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.